« SOLUBILITY 6.
S.N.Bhattachar,
E.J.Perkins, J.S.Tan, L.J.Burns. Effect of gastric pH on the pharmacokinetics of a bcs class II compound in dogs: Utilization of an artificial stomach and duodenum dissolution model and gastroplus,™ simulations to predict absorption. J. Pharm. Sci. 100, 4756–4765 (2011).
7. E.S.Kostewicz, B.Abrahamsson,
M.Brewster,
J.Brouwers, J.Butler,
S.Carlert, P.A.Dickinson, J.Dressman, R.Holm, S.Klein,
J.Mann,
M.McAllister, M.Minekus,
U.Muenster, A.Müllertz,
M.Verwei,
M.Vertzoni, W.Weitschies,
P.Augustijns. In vitro models for the prediction of in vivo performance of oral dosage forms. Eur. J. Pharmaceut. Sci. in press (2013).
8. 9.
R.Borchardt. Drug Design with ADME in mind: recent paradigm shifts in discovery. In
C.G.Kruse, H.Timmerman (eds.). Towards Drugs of the Future. IOS Press, 53-74 (2008).
C.A.Lipinski, F.Lombardo,
B.W.Dominy, P.J.Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23(1-3), 3-25 (1997).
10.
C.A.Lipinski. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discovery Today: Technologies 1(4), 337-341 (2004).
11.
J.Baell,
M.Congreve, P.Leeson, C.Abad-Zapatero. Ask the Experts: Past, present and future of the rule of five. Future Med. Chem. 5(7), 745-752 (2013).
12.
R.Panchagnula,
N.S.Thomas. Biopharmaceutics and pharmacokinetics in drug research. Int. J. Pharmaceutics 201, 131-150 (2000).
13.
L.Benet. EDAN. Leuven, Belgium. March 18-20, 2007.
14.
R.Morphy. Selective multitargeted drugs. In: Polypharmacology in Drug Discovery.
J.-U.Peters (ed.) Wiley and Sons, 47-262 (2012).
15.
A.T.M.Serajuddin. Salt formation to improve drug solubility. Adv. Drug Deliv. Rev., 59(7), 603- 616 (2007).
16.
B.S.Sekhon, Pharmaceutical co-crystals – a review. Ars Pharmaceut. 50(3) 99-117 (2009)
.G.M.Khan. Controlled release oral dosage forms: some recent advances in matrix type drug delivery systems. The Sciences 1(5), 350-354 (2001).
17. M.Kushal,
M.Monali, M.Durgavati, P.Mittal,
S.Umesh,
S.Pragna. Oral controlled release drug delivery system: an overview. Int. Res. J. Pharmacy, 4(3), 70-76 (2013).
18.
P.Dey,
S.Maiti. Orodispersible tablets: A new trend in drug delivery. J. Nat. Sci. Biol. Med. 1(1), 2–5 (2010).
19. M.L.Buck. Alternative forms of oral drug delivery for pediatric patients. Pediatr. Pharm. 19(3), (2013).
20.
R.Lipp. The innovator pipeline: bioavailability challenges and advanced oral drug delivery opportunities. Am. Pharm. Rev. 16(3), 10-16 (2013).
21.
www.fda.gov. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER), Nov. 2009.
22.
G.P.Giacoia, P.Taylor-Zapata,
A.Zajicek. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the second workshop on pediatric formulations. Clin. Ther. 34(Suppl.), S1–S10 (2012).
23. J.Walsh,
S.Mills. Formulating better medicines for children: 4th European Paediatric Formulation Initiative Conference. Ther. Deliv. 4, 21–25 (2013).
24.
S.Stegemann. Patient centric drug delivery – a changing paradigm in healthcare provision. Health insight 3 – The future of the pharma industry. Apr. 24, 2013, Beirut, Lebanon.
25.
R.Lipp. Patient-centered design of drug delivery systems. BIT’s 1st annual symposium of drug delivery systems. Nov. 3-5, 2011, Shenzhen, China.
The benchmark for dissolution automation.
Automate the entire workfl ow – from media preparation to data reporting.
Automation as it relates to dissolution can mean several things. When we talk about automated dissolution at SOTAX, we mean full automation: Several unattended lots run in succession with full media preparation, measured dispensing to the vessels, and automated cleaning of the vessels between lots. The cued dissolution methods can be different, or the user can run the same product back to back to back…
By combining the legacy of the SOTAX and Zymark brands, we have merged decades of automation experience.
With hundreds of global installations, SOTAX continues to set the benchmark for fully automated dissolution.
www.sotax.com
www.americanpharmaceuticalreview.com |
| 35
»
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156